Performance of fecal inflammatory biomarkers to identify watery shigellosis: Findings from the Enterics for Global Health (EFGH) Shigella surveillance study.

BACKGROUND

Current syndromic guidelines for diarrhea treatment miss watery Shigella cases, leading to undertreatment of children who may benefit. Incorporating fecal inflammatory biomarkers into diagnosis may improve case identification.

METHODS

We conducted an ancillary analysis using samples from six sites (The Gambia, Kenya, Malawi, Bangladesh, Pakistan, and Peru) from the Enterics for Global Health (EFGH)-Shigella surveillance study, a facility-based hybrid study of children aged 6-35 months with diarrhea. Four fecal biomarkers were quantified by enzyme-linked immunosorbent assays at enrollment: myeloperoxidase, calprotectin, neutrophil gelatinase-associated lipocalin (lipocalin-2), and hemoglobin. An ensemble model with leave-one-site-out cross-validation was used to predict watery shigellosis, incorporating biomarkers and nine clinical and socio-economic predictors. We compared the predictive performance of the algorithm using: a) all predictors (including biomarkers); b) all non-biomarker predictors; c) all predictors (with selected biomarkers).

RESULTS

Between June 2022 and August 2024, a total of 4,191/9,476 (44.2%) children presented with watery diarrhea (non-bloody) and had their whole stool tested for the biomarkers and 4,083 stool samples or rectal swabs were tested by qPCR; 735 (18.0%) had Shigella-attributable diarrhea by qPCR. The full model incorporating all 13 predictors achieved an area under the curve (AUC) of 0.75 [95% CI: 0.67-0.78], with a sensitivity of 0.67 and specificity of 0.75. Excluding biomarkers reduced model performance by 8% (AUC 0.67, 95% CI: 0.61-0.70). Adding hemoglobin alone improved the model's discriminatory ability by 7%, while further adding myeloperoxidase had marginal contribution (1%), and lipocalin-2 (0%) and calprotectin none (0%).

CONCLUSION

Fecal hemoglobin substantially improved prediction scores for watery shigellosis. Consequently, implementation of point-of-care assays for hemoglobin could improve clinical diagnosis in these settings and inform appropriate antibiotic treatment.